The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Is Lovacor cost-effective therapy?

    The answer (in the UK at least) is yes when taken by patients after their first heart attack.

    Using cost effectiveness mathematical models for cost for life years gained and cost per death avoided, Lovacor (aka Omacor) (omega-3-acid ethyl esters) when taken as a standard post-heart attack prevention treatment seems warranted both on the basis of the efficacy and the cost-effectiveness at 4 years and over a lifetime.

    The benefits offered by Lovacor are in addition to the benefits from taking statins and other prophylactic treatments.

    4/10/07 23:02 JR

    Leave a Comment

    You must be logged in to post a comment.